Company intelligence / Profile preview

PNAS Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

PNAS Therapeutics is a pre-clinical stage biotechnology company developing the Encapsula drug delivery platform, which enables stable vaccine delivery and optimizes administration of advanced treatments such as biologics, DNA/RNA, and cell therapies. The system enhances local drug delivery through improved bioavailability and targeting, with versatility for solid tumor applications and controlled release mechanisms for dermatology. No clinical results have been reported yet as the company remains in pre-clinical development[1][2].

Therapeutic areas: OncologyDermatology
Modalities: BiologicsDNA/RNA therapeuticsCell therapiesVaccines (stable delivery)
Industry: Biotech

Beyond the preview

Go deeper on PNAS Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNAS Therapeutics.

Explore the full profile